Have a question?

Contact us today!

Early Phase Clinical Trials

Helping our clients navigate their Phase I-IB studies

PPD’s early development services keeps an eye toward supporting your later-phase programs.

Phase I and IB trials represent the first practical tests of your compound’s clinical relevance and commercial viability. They are the culmination of years or even decades of research. Moreover, they set the stage for subsequent studies that will ultimately determine your compound’s efficacy, safety and positive impact on patient’s lives.

Maximizing success in early phase development requires a highly coordinated effort to anticipate potential challenges, recruit the right patients, engage top investigators and design a trial that will build a platform for later-stage success.

PPD’s dedicated team of global experts in early development and clinical pharmacology perform a critical assessment of your compound’s unique attributes to identify areas of strength and potential weakness that could impact the outcome of your trial and subsequent trials. Next, the team develops an integrated, early-phase program that leverages our facilities, site network, operational expertise and development experience to execute your trial in patients and/or healthy volunteers. Each step of the process is conducted with an eye toward supporting later-phase programs and regulatory submissions.

0 +

Phase I studies conducted in the past five years.

0 +

Households in our patient database.

PPD’s Early Development and Clinical Pharmacology Solutions

Our streamlined services help establish proof-of-concept by reducing time and cost from your development timeline.


PPD’s early development services provide:

Three strategically located PPD clinical research units (CRUs) located in Austin, Texas, Orlando, Florida and Las Vegas, Nevada.
With a dedicated team of early development professionals, PPD’s early development services group helps to execute Phase I and IB trials that accelerate your trial and contain costs.
Global locations
Access to a global network of early-phase research sites that conduct studies in general and specialty populations.
Unprecedented access to global patients via Accelerated Enrollment Solutions (AES), PPD’s industry-leading patient recruitment engine.
A range of consulting services for asset planning in the earliest phases of development and regulatory strategy assessment to mitigate risk.
Support early phase trials including customized assays for drug product evaluation as well as bioanalytical and pharmacokinetic assays.

Learn more about our Phase I capabilities


With over 100 studies awarded through our global network in the past five years, our areas of expertise include: renal impairment, hepatic impairment, Japanese Bridging, Chinese Bridging in China and NHV studies.

Early Development Services for Neurodegenerative Diseases

Early Development Services for Neurodegenerative Diseases

PPD’s early development services create an integrated approach for your neurodegenerative disease studies, including access to the right sites and the right patients. We have an established neuroscience team that will focus on your study startup. Our team will work closely with you to help deliver your life-changing therapy to patients as quickly as possible.

Explore Early Development Services for Neurodegenerative Studies

Featured Resources